FATE THERAPEUTICS INC Contract with Customer, Liability, Noncurrent
FATE THERAPEUTICS INC (FATE) had Contract with Customer, Liability, Noncurrent of $0 as of 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent › Deferred Revenue, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2023-02-28
- 2022-12-31: Contract with Customer, Liability, Noncurrent $0.00.
- 2022-09-30: Contract with Customer, Liability, Noncurrent $12.41M.
- 2022-06-30: Contract with Customer, Liability, Noncurrent $17.74M.
- 2022-03-31: Contract with Customer, Liability, Noncurrent $22.53M.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2022-09-30 | $12.41M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $17.74M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $22.53M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $27.12M 10-K · filed 2023-02-28 |
| 2021-09-30 | $32.56M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $38.92M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $43.02M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $46.02M 10-K · filed 2022-02-28 |
| 2020-09-30 | $49.38M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $54.69M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $3.12M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $3.77M 10-K · filed 2021-02-24 |
| 2019-09-30 | $4.50M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $5.24M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $6.38M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $7.50M 10-K · filed 2020-03-02 |
| 2018-09-30 | $8.00M 10-Q · filed 2018-11-01 |
| 2017-12-31 | $724.00K 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |